RxDoctor Payments Data

Rodolfo Botello

Psychiatric/Mental Health · El Paso, TXNPI 1396441259

Payments from drug & device makers

$2,489in general payments, 2019–2025

Across 193 payments — averaging $12.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$554
  • Otsuka America Pharmaceutical, Inc.$357
  • Neurocrine Biosciences, Inc.$349
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$250
  • Corium, LLC$202
  • Axsome Therapeutics, Inc.$198
  • plus $580 from 7 others

What the payments were for

  • Food & beverage$2,489100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,489 in reported general payments places this provider in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$42,193
Medicare patients
127
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine12$114,987
Invega TrinzaPaliperidone Palmitate11$94,086
Invega SustennaPaliperidone Palmitate31$94,043
RexultiBrexpiprazole46$65,944
VraylarCariprazine Hcl29$45,822
Aripiprazole409$32,921
Paliperidone ErPaliperidone117$25,841
CaplytaLumateperone Tosylate14$24,168
LybalviOlanzapine/Samidorphan Malate14$22,847
Oxcarbazepine283$22,190
Olanzapine OdtOlanzapine24$21,576
Clozapine131$16,241
Divalproex Sodium ErDivalproex Sodium134$12,733
Risperidone380$9,784
Quetiapine Fumarate372$9,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$99$188,12942 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$15$114,98712 claims
Otsuka America Pharmaceutical, Inc.Rexulti$357$65,94446 claims
AbbVieVraylar$554$45,82229 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$250$24,16814 claims
Alkermes, Inc.Lybalvi$168$22,84714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →